Wedbush analyst Dan Ives’ new price target for the electric vehicle maker still implies an upside of nearly 32% from Tesla’s Friday close.
Related Posts
Micron stock headed for worst day since 2020 after disappointing guidance
Micron’s stock plummeted on Thursday following the company’s earnings report and its weaker-than-expected guidance for the second quarter.
Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro
Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its diabetes drug Mounjaro.
Jefferies says buy this pharmaceutical play, sees more than 100% upside from here
This pharmaceutical company’s recent drug developments could spell more gains ahead, according to Jefferies.